Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Telomir Pharmaceuticals, Inc. Common Stock (TELO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/02/2025: TELO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.26% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.54M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.52 - 8.40 | Updated Date 06/29/2025 |
52 Weeks Range 1.52 - 8.40 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -391.62% | Return on Equity (TTM) -872.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46827162 | Price to Sales(TTM) - |
Enterprise Value 46827162 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 29762700 | Shares Floating 17618311 |
Shares Outstanding 29762700 | Shares Floating 17618311 | ||
Percent Insiders 34.17 | Percent Institutions 12.53 |
Upturn AI SWOT
Telomir Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on developing and commercializing Telomir-1, a small molecule compound targeting telomere attrition for age-related diseases. Founded relatively recently, it is in its early stages of development.
Core Business Areas
- Pharmaceutical Development: Researching, developing, and potentially commercializing Telomir-1 as a therapeutic for age-related diseases.
Leadership and Structure
Information on the specific leadership team and organizational structure is limited and subject to change as the company is pre-clinical stage.
Top Products and Market Share
Key Offerings
- Telomir-1: A small molecule compound designed to address telomere attrition, the shortening of protective caps on DNA strands, which is linked to aging and age-related diseases. The company currently has no market share as the drug is in pre-clinical stage. Competitors focus on addressing the symptoms of diseases associated with aging, but few directly target telomere attrition.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The segment Telomir operates in, targeting aging and age-related diseases, is attracting increased attention and investment.
Positioning
Telomir Pharmaceuticals is positioned as a pre-clinical stage company focused on a novel approach (telomere attrition) to address age-related diseases. This gives them a unique position, but also represents higher risk.
Total Addressable Market (TAM)
The TAM for age-related disease therapies is potentially very large, estimated to be in the hundreds of billions of dollars. Telomir is positioned to potentially capture a portion of this market if Telomir-1 successfully completes clinical trials and gains regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (targeting telomeres)
- Potential for first-in-class treatment
- Focus on a large and growing market (age-related diseases)
Weaknesses
- Pre-clinical stage (high risk)
- Limited financial resources
- No approved products or revenue
Opportunities
- Successful completion of clinical trials
- Partnerships with larger pharmaceutical companies
- Expansion to new therapeutic areas
Threats
- Failure of clinical trials
- Regulatory hurdles
- Competition from existing therapies
- Competition from other companies targeting aging
Competitors and Market Share
Key Competitors
- CRVS
- BLUE
- VERV
Competitive Landscape
The competitive landscape is diverse, with both established pharmaceutical companies and smaller biotech firms pursuing different approaches to address age-related diseases. Telomir Pharmaceuticals' competitive advantage lies in its novel telomere-targeting approach, but it faces the challenges of being a pre-clinical stage company with limited resources.
Growth Trajectory and Initiatives
Historical Growth: No historical growth in revenue due to pre-clinical stage.
Future Projections: Future growth is entirely dependent on successful clinical trials, regulatory approvals, and potential commercialization or partnerships.
Recent Initiatives: Recent strategic initiatives likely include advancing Telomir-1 through pre-clinical development and securing funding.
Summary
Telomir Pharmaceuticals is a highly speculative pre-clinical stage company focused on a novel therapeutic approach targeting telomeres for age-related diseases. Its success hinges on the successful development and commercialization of Telomir-1. The company faces significant risks associated with clinical trials, regulatory approvals, and competition. The company needs to make more partnership decisions to secure funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Data Providers
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment in Telomir Pharmaceuticals is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telomir Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2024-02-09 | Chairman of the Board & CEO Mr. Erez Aminov | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telomirpharma.com |
Full time employees - | Website https://telomirpharma.com | ||
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.